October 15, 2024: MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Last patient treated in MaaT Pharma’s Phase 3 ARES clinical trial Topline results publication now expected in January 2025 Positive DSMB review of Phase 3 ARES trial announced in Q4 2023, with a [...] 